What FDA Rules Apply to Remote Patient Monitoring (RPM) Devices?

Remote patient monitoring lets clinicians track a patient’s health data outside the traditional clinic, from heart rate and glucose levels to blood pressure and oxygen saturation. As demand grows, so does regulatory scrutiny. If you build or manage RPM technology, you need to know exactly which FDA rules apply before you market your device. MedLaunch guides medical device manufacturers and regulatory affairs professionals through that path, turning a detailed set of requirements into clear, manageable steps.

This post breaks down the RPM regulatory framework, from device classification through post-market obligations, so you know what to expect and where to focus first.

Key Summary: FDA Rules for RPM Devices at a Glance

Here are the essential FDA rules and classifications that apply to most RPM devices:

• Device classification: Most RPM devices fall into Class I or Class II, based on risk. Your class drives your regulatory pathway.
• 510(k) clearance: Many Class II RPM devices require a 510(k) premarket notification to prove substantial equivalence to a legally marketed predicate device.
• Quality System Regulation (QSR): Manufacturers must comply with 21 CFR Part 820, now aligned with ISO 13485 under the Quality Management System Regulation (QMSR), effective February 2, 2026.
• Labeling requirements: Devices must meet 21 CFR Part 801 for clear, accurate labeling and instructions for use.
• Unique Device Identification (UDI): Most devices need a UDI under 21 CFR Part 830.
• Post-market surveillance: Manufacturers must report adverse events through Medical Device Reporting (MDR) under 21 CFR Part 803.
• Software considerations: RPM software may qualify as Software as a Medical Device (SaMD) and trigger additional cybersecurity and software lifecycle expectations.

The rest of this guide explains each rule in plain terms.

FDA Classifications for RPM Devices

The FDA sorts every medical device into one of three classes based on risk. Your class sets the foundation for your entire compliance plan, so identify it early.

Class I: Low Risk

Class I devices carry the lowest risk and the lightest regulatory burden. Many are exempt from premarket notification. Some basic RPM accessories or low-risk monitoring components may land here. Most Class I devices still need to follow general controls, including registration, listing, and labeling rules.

Class II: Moderate Risk

Most RPM devices fall into Class II. These devices, such as connected blood pressure monitors, pulse oximeters, and continuous glucose monitors, carry a moderate risk and usually require a 510(k) clearance. Class II devices follow general controls plus special controls, which may include performance standards and specific labeling.

Class III: High Risk

Class III devices support or sustain life, or present a high potential risk. These require premarket approval (PMA), a more rigorous pathway than a 510(k). Few standalone RPM devices reach Class III, but it matters if your device is part of a higher-risk system.

So what? Confirming your classification first tells you which pathway, documentation, and timeline to plan for. Get this wrong, and you risk costly rework later.

510(k) Clearance Requirements

For most Class II RPM devices, the 510(k) premarket notification is your route to market. The goal is to show your device is substantially equivalent to a legally marketed predicate device.

A strong 510(k) submission demonstrates that your device:

• Has the same intended use as your chosen predicate device.
• Shares the same technological characteristics, or shows that any differences do not raise new safety or effectiveness questions.
• Performs as intended, backed by verification and validation data.

What to Prepare

Your submission should include a clear device description, your predicate comparison, performance testing, labeling, and applicable software documentation. Since October 1, 2023, the FDA requires most 510(k) submissions through the electronic eSTAR template. A complete eSTAR helps you avoid technical screening holds and keeps your review on track.

Quality System Regulation (QSR) and 21 CFR Part 820

FDA medical device compliance does not stop at clearance. If you manufacture RPM devices, you must follow the Quality System Regulation under 21 CFR Part 820. This rule governs how you design, produce, and maintain your device.

A compliant quality system covers:

• Design controls: Documented design inputs, outputs, verification, and validation.
• Document and record control: Clear procedures and traceable records.
• Production and process controls: Consistent, repeatable manufacturing.
• Corrective and preventive action (CAPA): A system to find, fix, and prevent problems.

The Shift to QMSR

The FDA has aligned Part 820 with ISO 13485:2016 under the new Quality Management System Regulation (QMSR), which took effect on February 2, 2026. If you already follow ISO 13485, you have a strong head start. If not, now is the time to close the gap.

Labeling Requirements Under 21 CFR Part 801

Labeling is one of the most overlooked parts of the RPM regulatory framework, yet a small error can stall your launch. Your labeling must meet 21 CFR Part 801, which sets the rules for clear, accurate, and non-misleading information.

Strong RPM device labeling includes:

• Intended use and indications: A clear statement of what your device does and who it serves.
• Instructions for use: Directions that a real user can follow safely, especially for at-home patients.
• Warnings and precautions: Plain-language guidance on risks and limitations.
• Unique Device Identifier (UDI): A UDI under 21 CFR Part 830 for traceability.

For RPM devices used by patients at home, usability matters even more. Clear instructions reduce use errors and support patient safety.

Post-Market Surveillance Obligations

Your responsibilities continue after your device reaches the market. Post-market surveillance helps the FDA and your team track real-world performance and respond quickly to problems.

Medical Device Reporting (MDR)

Under 21 CFR Part 803, you must report certain adverse events to the FDA. This includes incidents where your device may have caused or contributed to a death or serious injury, or where a malfunction could lead to harm if it recurs.

Other Post-Market Duties

• Complaint handling: Maintain a system to log, investigate, and resolve complaints.
• Corrections and removals: Report certain field corrections and recalls under 21 CFR Part 806.
• Ongoing software updates: For connected RPM devices, plan for cybersecurity monitoring and patch management across the product lifecycle.

Special Consideration: RPM Software as a Medical Device

Many RPM products rely on software to collect, transmit, and display patient data. When software performs a medical function on its own, it may qualify as Software as a Medical Device (SaMD).

If your RPM software qualifies, plan for:

• Software lifecycle processes aligned with IEC 62304.
• Cybersecurity controls to protect patient data and device function.
• Risk management under ISO 14971, with software hazards traced to controls.

Treat your software with the same rigor as your hardware. Reviewers increasingly expect strong software and cybersecurity documentation in RPM submissions.

Bring Your RPM Device to Market With Confidence

The FDA rules for RPM devices follow a clear logic once you break them down: classify your device, choose the right pathway, build a compliant quality system, get your labeling right, and maintain strong post-market surveillance. Handle each step with care, and you reduce your risk of delays, findings, and costly rework.

You do not have to work through this alone. MedLaunch helps RPM manufacturers and regulatory affairs teams turn these requirements into a clear, step-by-step plan, from classification through clearance and beyond. Contact MedLaunch today to schedule a consultation and give your RPM device a smoother, more confident path to market.

Tags: quality management system, remote patient monitoring device, RPM device